ARTICLE | Clinical News

Abide begins Phase Ib trial for neuroinflammatory pain candidate ABX-1431

October 20, 2017 12:31 AM UTC

Abide Therapeutics Inc. (San Diego, Calif.) began a crossover Phase Ib trial of ABX-1431 to treat neuroinflammatory disorders associated with central pain. ABX-1431 is a small molecule inhibitor of monoglyceride lipase (MGLL; MAGL), which regulates 2-arachidonoylglycerol (2-AG).

The double-blind, placebo-controlled, U.K. study will evaluate once-daily 20mg oral ABX-1431 for 7-9 weeks in up to 32 patients with chronic pain due to neuromyelitis optica spectrum disorder, longitudinally extensive transverse myelitis, multiple sclerosis or transverses myelitis. The primary endpoint is change from baseline to the last 7 days of each 2-week treatment period in pain numeric rating scale (NRS-11) score. Secondary endpoints include Short Form Brief Pain Inventory (SF-BPI), Short Form McGill Pain Questionnaire-2 (SF-MPQ-2) and Patient Global Impression of Change (PGI-C) scores, proportion of patients achieving and maintaining >30% and >50% reductions in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis, actigraphically estimated parameters of sleep and general activity measured by percentage of sedentary time and moderate to high intensity activity, sleep interference and pharmacokinetics...